Multiple sclerosis drugs: how much bang for the buck?

Lancet Neurol. 2015 May;14(5):460-1. doi: 10.1016/S1474-4422(15)00016-2. Epub 2015 Apr 1.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • Cost-Benefit Analysis*
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferon-beta / therapeutic use*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Peptides / therapeutic use*
  • Treatment Outcome*

Substances

  • Immunologic Factors
  • Peptides
  • Interferon-beta